EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A cynomolgus monkey E. coli urinary tract infection model confirms efficacy of new FimH vaccine candidates

Laurent Chorro, Tara Ciolino, Caresse Lynn Torres, Arthur Illenberger, JohnPaul Aglione, Paula Corts, Jacqueline Lypowy, Christopher Ponce, Annalena La Porte, Deborah Burt, Gretchen L Volberg, Lila Ramaiah und 6 weitere

Infection and Immunity · 2024

DOI: 10.1128/iai.00169-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Infection and Immunity, 2024. Verfasst von Laurent Chorro und 17 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Vaccine Research and Development, Pearl River, New York, USA. Hauptthemen laut MEDLINE: Adhesins, Escherichia coli, Escherichia coli Infections, Urinary Tract Infections, Fimbriae Proteins. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The increase in urinary tract infections (UTI) caused by antibiotic-resistant Escherichia coli requires the development of new therapeutic agents and prophylactic vaccines. To evaluate the efficacy of new lead candidates, we implemented a cynomolgus macaque UTI challenge model that mimics human uncomplicated cystitis in response to transurethral challenge with a multidrug-resistant (MDR) E. coli serotype O25b ST131 isolate. E. coli fimbrial adhesin FimH and O-antigens are separately under clinical evaluation by others as vaccine candidates to prevent UTI and invasive urosepsis disease, respectively. Accordingly, we assessed the protective efficacy of three 50-µg intramuscular doses of a novel recombinant FimH antigen adjuvanted with liposomal QS21/MPLA compared with saline placebo in groups of nine animals. A third group was vaccinated with this FimH formulation in combination with 1 µg each of a four-valent mixture of serotype O1a, O2, O6, and O25b O-antigen CRM 197 lattice glycoconjugates. Both vaccines elicited high levels of serum FimH IgG and adhesin blocking antibodies at the time of bacterial challenge and, for the combination group, O-antigen-specific antibodies. Following bacterial challenge, both vaccinated groups showed >200- and >700-fold reduction in bacteriuria at day 2 and day 7 post-infection compared with placebo, respectively. In parallel, both vaccines significantly reduced levels of inflammatory biomarkers IL-8 and myeloperoxidase in the urine at day 2 post-infection relative to placebo. Results provide preclinical proof-of-concept for the prevention of an MDR UTI infection by these new vaccine formulations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adhesins, Escherichia coliEscherichia coli InfectionsUrinary Tract InfectionsFimbriae ProteinsMacaca fascicularisDisease Models, AnimalEscherichia coli VaccinesEscherichia coliAnimalsAntibodies, BacterialFemale

Stichwörter der Autor:innen

Escherichia coliFimHUPECUTIcystitisnon-human primate

Substanzen

Adhesins, Escherichia colifimH protein, E coliFimbriae ProteinsEscherichia coli VaccinesAntibodies, Bacterial

Autor:innen und Institutionen

  • Pfizer Vaccine Research and Development, Pearl River, New York, USA.
  • Pfizer Drug Safety Research and Development, Groton, Connecticut, USA.
  • Pfizer Drug Safety Research and Development, Pearl River, New York, USA.
  • Pfizer Research Biostatistics, Collegeville, Pennsylvania, USA.

ORCID-Profile: Robert G K Donald

Zitieren

APA

Chorro, L., Ciolino, T., Torres, C. L., Illenberger, A., Aglione, J., Corts, P., Lypowy, J., Ponce, C., La Porte, A., Burt, D., Volberg, G. L., Ramaiah, L., McGovern, K., Hu, J., Anderson, A. S., Silmon de Monerri, N. C., Kanevsky, I., & Donald, R. G. K. (2024). A cynomolgus monkey E. coli urinary tract infection model confirms efficacy of new FimH vaccine candidates. Infection and Immunity. https://doi.org/10.1128/iai.00169-24

Vancouver

Chorro L, Ciolino T, Torres CL, Illenberger A, Aglione J, Corts P, et al. A cynomolgus monkey E. coli urinary tract infection model confirms efficacy of new FimH vaccine candidates. Infection and Immunity. 2024. doi:10.1128/iai.00169-24

BibTeX
@article{Chorro2024,
  author = {Chorro, Laurent and Ciolino, Tara and Torres, Caresse Lynn and Illenberger, Arthur and Aglione, JohnPaul and Corts, Paula and Lypowy, Jacqueline and Ponce, Christopher and La Porte, Annalena and Burt, Deborah and Volberg, Gretchen L and Ramaiah, Lila and McGovern, Kathryn and Hu, Jianfang and Anderson, Annaliesa S and Silmon de Monerri, Natalie C and Kanevsky, Isis and Donald, Robert G K},
  title = {A cynomolgus monkey E. coli urinary tract infection model confirms efficacy of new FimH vaccine candidates},
  journal = {Infection and Immunity},
  year = {2024},
  doi = {10.1128/iai.00169-24}
}
Kostenlos starten →